Prostate Cell News Volume 13.15 | Apr 29 2022

    By
    Ishira
    -
    0
    31







    2022-04-29 | PCN 13.15


    Prostate Cell News by STEMCELL Technologies
    Vol. 13.15 – 29 April, 2022
    TOP STORY

    HOXB13 Suppresses De Novo Lipogenesis through HDAC3-Mediated Epigenetic Reprogramming in Prostate Cancer

    HOXB13 loss or G84E mutation led to lipid accumulation in prostate cancer cells, thereby promoting cell motility and xenograft tumor metastasis, which was mitigated by pharmaceutical inhibition of fatty acid synthase.
    [Nature Genetics]

    Abstract
    Tips to prepare for your next conference or networking event
    PUBLICATIONSRanked by the impact factor of the journal

    A MYC Inhibitor Selectively Alters the MYC and MAX Cistromes and Modulates the Epigenomic Landscape to Regulate Target Gene Expression

    MYCi975 synergistically sensitized resistant prostate cancer cells to enzalutamide and estrogen receptor–positive breast cancer cells to 4-hydroxytamoxifen.
    [Science Advances]

    Full Article

    ASCL1 Activates Neuronal Stem Cell-Like Lineage Programming through Remodeling of the Chromatin Landscape in Prostate Cancer

    Scientists provided insights into the epigenetic alterations induced by androgen receptor pathway inhibitors (ARPIs), governed by ASCL1, provided a proof of principle of targeting ASCL1 to reverse neuroendocrine phenotype, supported luminal conversion and re-addiction to ARPIs.
    [Nature Communications]

    Full Article

    Identifying Phased Mutations and Complex Rearrangements in Human Prostate Cancer Cell Lines through Linked-Read Whole Genome Sequencing

    Researchers comprehensively characterized phased genomic alterations in the commonly used prostate cancer cell lines, providing a useful resource for future prostate cancer research.
    [Molecular Cancer Research]

    Abstract

    G9a Inhibition by CM-272: Developing a Novel Anti-Tumoral Strategy for Castration-Resistant Prostate Cancer Using 2D and 3D In Vitro Models

    Investigators concluded that inhibition of G9a methyltransferase activity by CM-272 has anti-tumor effect in prostate cancer cells, holding therapeutic potential against CRPC.
    [Biomedicine & Pharmacotherapy]

    Full ArticleGraphical Abstract

    High Intratumoral Dihydrotestosterone is Associated with Antiandrogen Resistance in VCaP Prostate Cancer Xenografts in Castrated Mice

    The presence of an androgen synthesis, independent of CYP17A1 activity, has been shown to exist in prostate cancer cells, and therefore, novel androgen synthesis inhibitors were needed for the treatment of enzalutamide-resistant CRPC tumors that did not respond to abiraterone.
    [iScience]

    AbstractFull ArticleGraphical Abstract

    ETS Transcription Factor ELF3 (ESE-1) Is a Cell Cycle Regulator in Benign and Malignant Prostate

    Silencing ELF3 in both benign prostate and prostate cancer cell lines resulted in decreased colony forming ability, inhibition of cell migration and reduced cell viability due to cell cycle arrest, establishing ELF3 as a cell cycle regulator.
    [Febs Open Bio]

    AbstractFull Article

    Clinical Validation of a Circulating Tumor Cell Assay Using Density Centrifugation and Automated Immunofluorescence Microscopy

    Normal peripheral blood specimens spiked with cultured breast and prostate cancer cells and 47 clinical samples were used to validate assay performance.
    [American Journal of Clinical Pathology]

    Abstract

    Production and Conjugation of Truncated Recombinant Diphtheria Toxin to VEGFR-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line

    VGRNb-DT demonstrated a successful bioconjugation and variable concentrations were correlated with cell death in prostate cancer PC-3 cells.
    [Molecular Biotechnology]

    Abstract
    ON987CXN-may-728x90-2022
    REVIEWS

    P2Y Purinergic Signaling in Prostate Cancer: Emerging Insights into Pathophysiology and Therapy

    The authors review the pathological and immunomodulatory roles of P2Y purinergic nucleotide receptors in prostate cancer and their potential as therapeutic targets to address some of the clinical limitations in prostate cancer treatment.
    [Biochimica et Biophysica Acta-Reviews On Cancer]

    Abstract

    Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic Review

    Future studies are needed to verify the clinical usefulness of Proclarix in men with suspected prostate cancer before and after multiparametric MRI.
    [Molecular Diagnosis & Therapy]

    Abstract
    INDUSTRY AND POLICY NEWS

    First European Union Patient Dosed with 177Lu-PNT2002 in the Phase III SPLASH Trial

    POINT Biopharma Global, Inc. announced the first patient in the European Union has been dosed in the Phase III SPLASH trial investigating the use of 177Lu-PNT2002, a PSMA-targeted radioligand, in pre-chemotherapy metastatic CRPC.
    [POINT Biopharma Global, Inc.]

    Press Release
    FEATURED EVENT

    Danish Stem Cell Society (DASCS) 2022

    September 19 – 20, 2022
    Vejle, Denmark

    > See All Events

    JOB OPPORTUNITIES

    Research Investigator – Cancer Biology

    University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Group Leader – Translational Cancer Research

    University Hospital Frankfurt – Frankfurt, Germany

    Postdoctoral Fellow – Molecular Biology

    City of Hope – Duarte, California, United States

    Postdoctoral Research Associate – Neuroendocrine Prostate Cancer

    Washington State University – Spokane, Washington, United States

    Postdoctoral Research Fellow – Disease Pathogenesis

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter